The standard treatments for non-Hodgkin lymphoma (NHL), multiple myeloma, and Waldenstrom’s macroglobulinemia (WM) include radiation therapy and/or chemotherapy. However, a high percentage of patients don’t respond to therapy or experience a recurrence of their disease. Doctors are therefore seeking more effective treatments.
CB-839 is an investigational drug that works by inhibiting an enzyme involved in cancer metabolism called glutaminase. Glutamine is an important source of energy for many cancer cells. This study will investigate a novel approach to therapy by targeting an important fuel source that has the potential of inhibiting tumor cell growth and survival. Researchers want to find the highest dose of CB-839 that can be given safely in patients with NHL, multiple myeloma, or WM that has continued to grow or has come back despite two or more prior regimens of therapy. CB-839 is a capsule that is taken orally (by mouth).